To our knowledge, this is the first meta-analysis to evaluate the potential effect of PCSK9 inhibitors therapy on the risk of SCD and ventricular arrhythmias using data from RCTs. The gene discussed is PCSK9; the disease is Schnyder corneal dystrophy.